Hawaii's awarded Research Study to Relief Motor Fluctuations of Parkinson Disease Investigating Lu AF 28996 Agonist D1 & D2 Receptors. Honolulu, 2024

PARKINSON'S CTR

According to Lundbeck, Lu AF28996 has the potential to treat common symptoms in patients with moderate/advanced Parkinson's disease. Typically, patients gradually develop fluctuations in the control of their symptoms with poor or absent motor function (so called OFF episodes) and experience involuntary movements (dyskinesia). Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson's disease patients.

Both these symptoms are thought to be treated effectively with Lu AF28996. This compound has the potential to significantly improve the lives of patients with Parkinson's disease, many of whom today do not have effective treatment options. Hopefully we will be able to offer these patients much better symptom control in the future,"

PD patients with experience recognizable and predictable motor fluctuations, with at least 1.5 hours of OFF periods in the awake time, including predictable morning OFF episode are eligible to participate.

"Our team of neurologists, neuroscience specialists and researchers in Hawaii cannot be more proud to be part of this research to develop solutions for patients experiencing motor fluctuation" says Kore Liow, MD, Principal Investigator, Neurologist & Neuroscience Chair at Hawaii Pacific Neuroscience & Clinical Professor of Medicine (Neurology), University Hawaii JABSOM



CLINICAL TRIALS

For more information, See NIH Info or please contact:
Hawaii Parkinson's Disease Center & Hawaii Parkinson's Research Unit 2230 Liliha Street #104, HONOLULU, HI 96817, Research Hotline (808) 564-6141 info@HawaiiNeuroscience.com